MA32418B1 - Nouveau sel de metformine glycinate pour regulation de la glycemie - Google Patents

Nouveau sel de metformine glycinate pour regulation de la glycemie

Info

Publication number
MA32418B1
MA32418B1 MA33460A MA33460A MA32418B1 MA 32418 B1 MA32418 B1 MA 32418B1 MA 33460 A MA33460 A MA 33460A MA 33460 A MA33460 A MA 33460A MA 32418 B1 MA32418 B1 MA 32418B1
Authority
MA
Morocco
Prior art keywords
metformin
salt
glycine
glycinate
hydrochloride
Prior art date
Application number
MA33460A
Other languages
Arabic (ar)
English (en)
Inventor
Ochoa José Manuel Francisco Lara
Original Assignee
Silanes Sa De Cv Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32418(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silanes Sa De Cv Lab filed Critical Silanes Sa De Cv Lab
Publication of MA32418B1 publication Critical patent/MA32418B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Dans cette invention, un nouveau sel de 1,1 -diméthylbiguanide glycinate a été synthétisé, appelé metformine glycinate. Ledit sel présente des avantages sur d'autres sels de metformine. Lesdits avantages sont dûs, en premier lieu, au fait que le contre-ion de glycine présente lui-même des effets hypoglycémiques. De plus, ledit sel présente une absorption plus rapide, atteignant des concentrations plasmatiques supérieures à celles produites avec du chlorhydrate de metformine. La synthèse est obtenue à partir du sel de chlorhydrate de metformine, la metformine libre étant produite par libération du contre-ion de chlorhydrate, à l'aide d'une colonne échangeuse d'ions prévue à cet effet; la metformine base libérée est dissoute dans un milieu aqueux et, ultérieurement, de la glycine est ajoutée à température ambiante sous agitation constante; ensuite, le produit obtenu est chauffé jusqu'à ce qu'une solution concentrée soit produite, un solvant organique, lequel ne réagit pas avec les composants présents et dans lequel la glycine est insoluble, est ajouté afin de créer une insolubilité dans le milieu et favoriser la cristallisation du milieu saturé; tout ceci afin de précipiter la glycine en excès puis de la séparer par filtrage; le filtrat est concentré à nouveau jusqu'à obtenir la précipitation du sel de metformine de glycinate.
MA33460A 2008-06-26 2010-12-27 Nouveau sel de metformine glycinate pour regulation de la glycemie MA32418B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002665 WO2009144527A1 (fr) 2008-06-26 2008-06-26 Nouveau sel de metformine glycinate pour régulation de la glycémie

Publications (1)

Publication Number Publication Date
MA32418B1 true MA32418B1 (fr) 2011-06-01

Family

ID=40383805

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33460A MA32418B1 (fr) 2008-06-26 2010-12-27 Nouveau sel de metformine glycinate pour regulation de la glycemie

Country Status (26)

Country Link
US (2) US8703183B2 (fr)
EP (1) EP2303838B1 (fr)
JP (1) JP5551691B2 (fr)
KR (1) KR101522066B1 (fr)
CN (1) CN102159539B (fr)
AR (1) AR074159A1 (fr)
AU (1) AU2008357111B2 (fr)
BR (1) BRPI0822909B8 (fr)
CA (1) CA2729035C (fr)
CL (1) CL2009001484A1 (fr)
CY (1) CY1115098T1 (fr)
DK (1) DK2303838T3 (fr)
EC (1) ECSP10010719A (fr)
ES (1) ES2450148T3 (fr)
HR (1) HRP20140194T1 (fr)
JO (1) JO2884B1 (fr)
MA (1) MA32418B1 (fr)
MX (1) MX2011000135A (fr)
NI (1) NI201000234A (fr)
PE (1) PE20100257A1 (fr)
PL (1) PL2303838T3 (fr)
PT (1) PT2303838E (fr)
SI (1) SI2303838T1 (fr)
TN (2) TN2010000607A1 (fr)
UY (1) UY31945A (fr)
WO (1) WO2009144527A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008357111B2 (en) 2008-06-26 2013-05-09 Laboratorios Silanes, S.A. De C.V. A new metformin Glycinate salt for blood glucose control
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
CN103263405B (zh) * 2013-05-08 2015-04-22 南京医科大学 用于治疗糖尿病的药物组合物及其应用
WO2015042495A2 (fr) * 2013-09-22 2015-03-26 Jiva Pharma, Inc. Sels de metformine pour traiter le diabète de type 2
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
CA2947741A1 (fr) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions et procedes se rapportant a des sels ioniques de peptides
WO2015183794A1 (fr) * 2014-05-27 2015-12-03 City Of Hope Complexes d'agonistes de tgr5 pour le traitement du diabète et du cancer
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
CN105030745A (zh) * 2015-07-08 2015-11-11 南京医科大学 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用
WO2017031440A1 (fr) 2015-08-20 2017-02-23 Aseko, Inc. Conseiller de thérapie pour la gestion du diabète
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
WO2018060959A1 (fr) * 2016-09-30 2018-04-05 Laboratorios Silanes S.A. De C.V. Glycinate de metformine, compositions pharmaceutiques les comprenant, et leurs procédés d'utilisation
US11510886B2 (en) 2016-09-30 2022-11-29 Laboratorios Silanes, S.A. De C.V. Metformin amino acid compounds and methods of using the same
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568513A (fr)
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
DE1967138A1 (de) 1969-07-17 1977-11-10 Christian Brunnengraeber Chem Therapeutisches mittel
AT325632B (de) 1973-06-01 1975-10-27 Hurka Wilhelm Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids
FR2243684B1 (fr) 1973-09-19 1977-01-28 Semb
CH602612A5 (fr) * 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
JPS57179494A (en) 1981-04-30 1982-11-05 Mitsubishi Plastics Ind Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
AU738804B2 (en) 1997-12-08 2001-09-27 Bristol-Myers Squibb Company Novel salts of metformin and method
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003068209A1 (fr) * 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Sels de metformine a acides lipophiles
US7181457B2 (en) * 2003-05-28 2007-02-20 Pervasive Software, Inc. System and method for utilizing compression in database caches to facilitate access to database information
KR20060108692A (ko) 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
WO2005065675A1 (fr) 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Methode de traitement
WO2006086856A1 (fr) 2005-02-15 2006-08-24 Messadek, Jallal Compositions therapeutiques combinees et leurs procedes d’utilisation
ATE540690T1 (de) * 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
WO2007149313A1 (fr) * 2006-06-16 2007-12-27 Indigene Pharmaceuticals Inc. Lipoate de metformine r-(+) utilisé comme antidiabétique contr l'hyperglycémie diabétique et les complications diabétiques
NZ556735A (en) * 2007-07-24 2009-03-31 Vector Ltd Securing devices and equipotential bonding system
AU2008357111B2 (en) 2008-06-26 2013-05-09 Laboratorios Silanes, S.A. De C.V. A new metformin Glycinate salt for blood glucose control

Also Published As

Publication number Publication date
UY31945A (es) 2010-01-05
BRPI0822909A2 (pt) 2015-06-30
PL2303838T3 (pl) 2014-07-31
TN2010000607A1 (en) 2012-05-24
BRPI0822909B1 (pt) 2019-11-12
KR101522066B1 (ko) 2015-05-20
EP2303838A1 (fr) 2011-04-06
DK2303838T3 (en) 2014-03-03
EP2303838B1 (fr) 2013-12-04
PT2303838E (pt) 2014-03-10
CN102159539A (zh) 2011-08-17
AU2008357111A1 (en) 2009-12-03
JO2884B1 (en) 2015-03-15
CA2729035A1 (fr) 2009-12-03
ECSP10010719A (es) 2011-01-31
HRP20140194T1 (hr) 2014-06-20
US8703183B2 (en) 2014-04-22
NI201000234A (es) 2012-03-19
JP2011525900A (ja) 2011-09-29
PE20100257A1 (es) 2010-04-10
BRPI0822909B8 (pt) 2021-05-25
US20110171142A1 (en) 2011-07-14
TN2010000604A1 (en) 2012-05-24
KR20110042165A (ko) 2011-04-25
AR074159A1 (es) 2010-12-29
CY1115098T1 (el) 2016-12-14
CN102159539B (zh) 2014-04-16
SI2303838T1 (sl) 2014-07-31
MX2011000135A (es) 2011-02-25
JP5551691B2 (ja) 2014-07-16
WO2009144527A1 (fr) 2009-12-03
USRE46496E1 (en) 2017-08-01
AU2008357111B2 (en) 2013-05-09
ES2450148T3 (es) 2014-03-24
CA2729035C (fr) 2015-10-20
CL2009001484A1 (es) 2009-12-04

Similar Documents

Publication Publication Date Title
MA32418B1 (fr) Nouveau sel de metformine glycinate pour regulation de la glycemie
RU2550202C2 (ru) Способ синтеза эрготионеина и его аналогов
JP2003292484A (ja) γ−ヒドロキシアミノ酸誘導体及びモナティン類の製造方法
CN101480590A (zh) 磺酸盐双子表面活性剂及其制备方法
CN104826543A (zh) 一种含烷基酰胺乙基的季铵盐Gemini表面活性剂的制备方法
RU2019138212A (ru) Контейнер, содержащий композицию моющего средства, содержащую соли mgda и glda
ES2409834T3 (es) Procedimiento para la elaboración de mezclas que contienen sales de imidazolio
WO2015007630A1 (fr) Nouveaux sels, cristaux, complexes et dérivés d'acide diacétique de thréonine, procédé de préparation dudit acide et utilisation associée
CN106699586A (zh) 门冬氨酸鸟氨酸的制备方法
JP2007508367A5 (fr)
Dikusar et al. Synthesis of Schiff bases from 1-naphthylamine and vanillin, vanillal, and their O-acyl derivatives.
CN103073483A (zh) 一种甲哌卡因及其光学对映体的制备方法
CN101429136B (zh) 一种n-苄基羟胺及其盐酸盐的制备方法
CN106432004A (zh) 一种3‑砜基醇类化合物的合成方法
CN102432567B (zh) 一种环氧琥珀酸盐制备方法
CN100387586C (zh) 手性2-胺基-1-(6-氟-3,4-二氢苯并吡喃基)乙醇的合成方法
TW200408635A (en) Optically active β-aminoketones, optically active 1, 3-amino alcohols and processes for preparing them
CN103554025B (zh) 3-砒唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
EP0073715A1 (fr) Composés bromés utilisables dans des produits opacifiants
CN107586267A (zh) 一种牛磺酰胺盐酸盐(2‑氨基乙基磺酰胺盐酸盐)的合成方法
EP3153498A1 (fr) Procédé de préparation de phényl glycine à substitution n
JP5498862B2 (ja) カルボキシル基とアミド基を有する化合物及びその応用
Dudley et al. A synthesis of N-methylputrescine and of putrescine
FI73976C (fi) Foerfarande foer foerdelning av racematet s-(karboximetyl)-(r,s)-cystein i isomerer.
CN100567277C (zh) 一种含n五元芳香杂环甲脒及其盐的制备方法